A carregar...
Deubiquitylating enzymes and drug discovery: emerging opportunities
More than a decade after a Nobel Prize was awarded for the discovery of the ubiquitin–proteasome system and clinical approval of proteasome and ubiquitin E3 ligase inhibitors, first-generation deubiquitylating enzyme (DUB) inhibitors are now approaching clinical trials. However, although our knowled...
Na minha lista:
| Publicado no: | Nat Rev Drug Discov |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7097658/ https://ncbi.nlm.nih.gov/pubmed/28959952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrd.2017.152 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|